This content is protected against AI scraping.
Two medical marijuana companies (Bud & Mary’s and Tri-Mountain Pure) are stepping up in federal court to defend the government’s plan to lower cannabis’s drug classification from Schedule I to Schedule III. Anti-cannabis groups are suing to block this change, so these companies are officially joining the lawsuit to fight back. They have way too much skin in the game to just sit on the sidelines and hope the government wins the case for them.
What’s At Stake?
If the anti-cannabis groups win and block the policy change, it would be a massive setback. The companies argue it would hurt them in five major ways:
-
Financial Hits: They would lose standard business tax write-offs, costing them a ton of money.
-
Wasted Progress: Their current paperwork and official registrations with the DEA would be completely trashed.
-
Stalled Research: It would freeze clinical research, making it incredibly hard to develop new medical therapies for patients.
-
Corporate Gatekeeping: Banks, insurers, and everyday business vendors would likely refuse to work with them due to federal risks.
-
Hiring Struggles: It would scare off top talent—like scientists and executives—who don’t want to gamble with their professional licenses.
The Bottom Line
These companies have already invested heavy capital and time into pivoting their operations for this new regulatory era. With the DEA currently holding hearings on the future of cannabis reform, these operators are standing on business to protect their growth, their investments, and their patients.
This is a summary.
Please read the original article: Marijuana Companies Seek To Defend Trump’s Rescheduling Move By Intervening In Opponents’ Lawsuits
Original article written by Tom Angell. Published on July 1, 2026 by Marijuana Moment.







